PROG | Sponsors / Upcoming Abstracts

Optifinancial Newsletter - Knowledge is power - Brad Mitchell

This is not financial advice nor recommendations. This is purely our own thoughts and opinions regarding the matter discussed below for entertainment purposes. This is not advice and is never intended to be.

Disclosure: We own PROG securities/shares at the time of publication. This could affect my biases in my analysis.

 

Progenity | $1.15

  • Abstract information

  • Sponsorships

 

Abstract Information:

Progenity released a press release regarding their pill technology which will speak mostly about the OBDS but seems to also hint at the possibility to leverage their assessment methods with their Flagship DDS product.


Abstract 1: Will speak about ways to assess pill performance.

Abstract 2: Will speak and show how to assess performance.


These 2 abstracts show strength in the execution department for their technology pills. It also is starting to show many sponsors that Progenity has the leading edge for the technology pill market.

 

Sponsorships:

Here are the sponsors for CRS:

Potential undisclosed partners that could be involved with their OBDS platform:

Sanofi

Roche

Bristol Myers Squibb

Astrazeneca

Merck

Novartis

Final Thoughts:

Expecting more updates regarding their pill technology. I am hoping we get to hear about a licensing deal regarding Preecludia, however, the market is seeming to price in that we will never hear about the product line as it has been stopped.


If you go back to my article regarding Preecludia revenue. I never thought it would be a large impact on the company, but it was a possible solution to their cash problem that they are running into. The stock price has been very depressed and reflects the actual situation. I think for this stock price and company to be propelled forward, they need to resolve their cash.


I still see a few ways they can do this, but I am cautioning that if they do not act or have a resolution soon, they could find themselves in serious financial trouble.


My hope is that companies like Ionis and others keep Progenity afloat and fund their technology pipelines. I do see this company staying around though. I do not think they will be dismantled. When the situation seems so bleak, I am reminded that underneath these low prices is a extremely high potential and that is why I continue to hold. The technology is there. Just need to make sure we can see execution. (Adi mentioned that the back half of the year that they would tell us more about the large pharma partnerships regarding their OBDS.)

 

Current Price: $1.15

If they can endure the weather long enough:

10-12 Year Price Forecast (2030-2032):

Bear case: $390 a share or $64 billion in valuation

If Progenity takes a bit longer on their goals and commercializes in 2028, I believe they will still be driving 3-4 billion a year and could be trading at a PE of 20.

Bull case: $1,170 a share or $196 billion in valuation.

If Progenity can start commercialization in 2025 and progress their technology through multiple revenue streams, we could see solid dominance and incredible growth. I think they could capitalize on Humira and then further large molecules (tofacitinib & GLP-1). If their Ionis partnership pushes through as well (60 billion market by 2030), we could see 9-12 billion a year. And with a PE of 20.

Disclosure: We own PROG securities/shares at the time of publication

All stocks talked about we have invested in, and do not intend to give advice nor recommend acting upon the information.

 

Thanks for subscribing to the newsletter. If you find this information helps you, please share it with someone else! It will help us out greatly.


Until next week,

Brad Mitchell

and the Optifinancial Team

 

DISCLAIMER

Optifinancial is not a certified financial planner/advisor nor a certified financial analyst nor an economist nor a CPA ;nor an accountant nor a lawyer. Optifinancial is not a finance professional through formal education. Optifinancial believes in and takes pride in a sense of freedom, satisfaction, fulfillment and empowerment of money. The contents on this site/letter/email are for informational and entertainment purposes only and does not constitute financial, accounting, or legal advice. Optifinancial can’t promise that the information shared on our posts is appropriate for you or anyone else. By using our content, you agree to hold Optfinancial or any constituents related to Optifinancial harmless from any ramifications, financial or otherwise, that occur to you as a result of acting on information provided through our site, website, social media and newsletter.


PRIVACY POLICY

Optifinancial does not collect information about you other than (1) what you personally provide if you submit a comment (your email will not be published) or sign up for our newsletter updates and (2) what’s available through normal server logs and Google Analytics. Optifinancial won’t sell or disclose your information to others unless we have received prior written agreement from you (e.g., you agreed to let me share your comment on a post with other readers).


17350 State Highway 249

Ste 220 #3942

Houston, Texas 77064

brad@optifinancialnews.com

483 views0 comments

Recent Posts

See All